A reasonable chance it could cause serious harm or death.
Presence of Particulate matter: Particulate matter identified as glass.
| Brand name | DOXORUBICIN HYDROCHLORIDE |
| Generic name | DOXORUBICIN HYDROCHLORIDE |
| Active ingredient(s) | DOXORUBICIN HYDROCHLORIDE |
| Distributed by / for | Northstar Rx LLC., Memphis, TN 38141 |
| NDC | 72603-200-01 |
| Full product label | DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL), 25 mL single-dose vials, Sterile, Rx only, Manufactured for: Northstar Rx LLC., Memphis, TN 38141, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol, Gujarat, India, NDC 72603-200-01. |
| Recalling firm | SUN PHARMACEUTICAL INDUSTRIES INC |
| Distribution | U.S. Nationwide |
| Quantity | 675 vials |
| Recall initiated | 2026-05-12 |
| Report date | 2026-06-17 |
| Recall completed | — |
| Recall number | D-0580-2026 |
| Classification | Class I |
| FDA status | Ongoing |
| Origin on file | Princeton NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗